1.0 Executive Summary & Investment Recommendation

The investment thesis is predicated on a successful and ongoing strategic transformation that is shifting the company’s earnings profile towards higher-margin, higher-growth segments, a valuation that has yet to fully reflect this enhanced earnings power, and the substantial de-risking of the business following the resolution of the majority of its opioid-related litigation.

Cardinal Health is at a key inflection point. After years of being weighed down by litigation uncertainty and operational challenges within its Medical segment, the company is emerging as a more focused, efficient, and growth-oriented enterprise. Management’s strategic reorganization, which provides greater visibility into its high-growth businesses, coupled with an aggressive and disciplined capital deployment strategy focused on acquiring specialty physician service platforms, is fundamentally altering the company’s long-term value proposition.

The successful turnaround of the Global Medical Products and Distribution (GMPD) segment, which has returned to profitability and positive cash flow generation, provides a stable foundation and removes a significant drag on enterprise performance.¹ Concurrently, the Pharmaceutical and Specialty Solutions segment continues to exhibit robust growth, bolstered by the expansion into specialty services that create a sticky, high-value ecosystem around physician practices.

Financially, the company has demonstrated strong execution, delivering 9% non-GAAP diluted EPS growth in fiscal year (FY) 2025 and guiding for impressive 13% to 15% growth in FY26 to a range of $9.30 to $9.50.³ This growth is supported by strong free cash flow generation, which is projected to be between $2.75 billion and $3.25 billion in FY26, enabling the company to fund its growth initiatives while continuing its long-standing policy of returning significant capital to shareholders through dividends and share repurchases.⁴

While the stock has performed well since 2022, its current valuation, with a forward P/E multiple in line with peers, does not appear to fully discount the potential for sustained double-digit earnings growth and margin expansion. Key catalysts for further share price appreciation include continued margin improvement in the GMPD segment, successful integration and synergy realization from recent acquisitions, and the market’s growing recognition of CAH’s transition from a traditional low-margin distributor to a more diversified healthcare services company. The primary risks to the thesis include execution missteps in the ongoing business transformation, renewed pricing pressure in the core pharmaceutical distribution business, and potential macroeconomic headwinds impacting healthcare utilization.

2.0 Company Overview & Evolving Business Model

2.1 Corporate Profile

Cardinal Health, Inc. is a foundational component of the global healthcare ecosystem. Headquartered in Dublin, Ohio, the company operates as a globally integrated healthcare services and products company, providing customized solutions for a wide array of healthcare providers, including hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices.⁵ With a history spanning over 50 years, Cardinal Health has established a significant global presence, with operations in more than 30 countries and a workforce of approximately 48,000 employees.⁷ Its core function is to act as a critical intermediary, connecting patients, providers, payers, pharmacists, and manufacturers to enhance supply chain efficiency, coordinate care, and improve patient management.⁵

2.2 Strategic Reorganization (Effective January 2024)

A pivotal development for understanding the current investment case is the company’s strategic reorganization of its operating and reporting structure, which became effective on January 1, 2024.¹ This change was not merely an administrative reshuffling but a deliberate signal to the investment community about the company’s future strategic priorities. The new structure is designed to increase focus on core operations, provide greater transparency into performance, and accelerate growth in key areas. It replaced the previous two-segment structure (Pharmaceutical and Medical) with a more nuanced framework comprising three components:

• Pharmaceutical and Specialty Solutions: This remains the company’s largest segment by revenue and profit. It encompasses the traditional distribution of branded, generic, and over-the-counter pharmaceuticals to a diverse customer base. Critically, it also includes the company’s rapidly expanding and higher-margin specialty distribution business, which provides services to pharmaceutical manufacturers and healthcare providers for complex specialty pharmaceutical products.⁵
• Global Medical Products and Distribution (GMPD): This segment consolidates the U.S. and international manufacturing and distribution of medical, surgical, and laboratory products. It includes both national brand products and Cardinal Health’s own proprietary branded products, which are a key focus for margin improvement. This segment has been the subject of a multi-year turnaround effort aimed at mitigating inflation and improving operational efficiency.¹
• Other: This newly created category aggregates three of the company’s high-growth, higher-margin businesses, which were previously embedded within the broader segments. This separation provides investors with unprecedented visibility into their individual performance and growth trajectories. The “Other” category includes:

• at-Home Solutions: A direct-to-patient business serving individuals with chronic conditions. It comprises Edgepark, a leading medical supplies provider, and a business-to-business distribution service for home medical equipment providers and home health agencies.¹
• Nuclear and Precision Health Solutions (NPHS): A specialized business that operates a nationwide network of nuclear pharmacies and radiopharmaceutical manufacturing facilities, providing time-sensitive products for diagnostic imaging.⁵
• OptiFreight Logistics: A technology-enabled logistics management service that helps healthcare providers optimize their shipping and control freight spend. This business managed over 22 million parcel packages in FY24, demonstrating its significant scale.¹

This reorganization is a strategic communication tool. By isolating the “Other” businesses, management is explicitly highlighting its designated growth engines. Previously, their strong performance was obscured within the larger, lower-margin legacy segments. This new transparency allows analysts and investors to more accurately assess the value of these faster-growing, margin-accretive businesses. This structural change is intended to shift the investment narrative from Cardinal Health being a monolithic, low-margin distributor to a more dynamic sum-of-the-parts story, potentially justifying a higher valuation multiple over the long term as the market recognizes the value of these distinct operations.

2.3 Core Value Proposition & Differentiation

Cardinal Health’s fundamental value proposition is built on the immense scale of its distribution network, its deep logistical expertise, and its indispensable role within the U.S. healthcare supply chain.⁵ The company’s key differentiator lies in the breadth of its offerings, which uniquely span both the pharmaceutical and medical supply chains, complemented by a growing portfolio of value-added services in data analytics, logistics management, and practice management. This integrated model allows it to serve as a comprehensive partner to healthcare providers.

2.4 Geographic Footprint

While Cardinal Health is a global company with a presence in over 30 countries, its financial performance is overwhelmingly driven by the North American market, particularly the United States.⁷ The U.S. represents the largest and most developed healthcare distribution market in the world, accounting for over 40% of global revenue in the sector.¹⁰ The company’s infrastructure, customer relationships, and strategic focus are primarily concentrated within this region.

2.5 Key Customer Relationships & Dependency

The pharmaceutical distribution industry is characterized by significant customer concentration, where a small number of large pharmacy chains, hospital systems, and group purchasing organizations (GPOs) account for a substantial portion of revenue. The loss of the OptumRx contract, which created a headwind for revenue growth in FY25, is a clear example of this dependency and the material impact of contract renewals.¹² Maintaining strong relationships with key customers like CVS Health, which has a joint generic sourcing venture with Cardinal Health, is critical to the stability of the core business.¹⁴

3.0 Industry Analysis & Market Dynamics

3.1 Healthcare Distribution Industry Overview

The healthcare distribution industry serves as the vital link between manufacturers of pharmaceuticals and medical devices and the providers who dispense them to patients. It is a classic scale-based business, defined by high revenue volumes and very low operating margins. Success is contingent upon extreme logistical efficiency, sophisticated inventory management, and the ability to leverage immense purchasing power. The industry’s primary players, known as the “Big Three,” operate as an effective oligopoly in the U.S. market.

3.2 Market Size & Growth Trends

The global healthcare distribution market is a colossal and growing sector. Market size estimates place the value at over USD 1 trillion in 2023-2024, with various industry reports projecting a consolidated compound annual growth rate (CAGR) of approximately 7% through 2032.¹⁰ This steady growth is underpinned by non-cyclical demand and several powerful secular tailwinds. North America remains the largest single market, commanding over 40% of global revenue, driven by high per-capita healthcare spending and advanced infrastructure.¹⁰

3.3 Structural Growth Drivers

The industry’s consistent growth is propelled by several durable, long-term trends:

• Aging Population and Rising Burden of Chronic Disease: Demographic shifts, particularly in developed nations, are leading to an older population with a higher incidence of chronic conditions such as diabetes, cardiovascular disease, and cancer.¹⁰ These conditions often require long-term medication regimens, creating a stable and growing baseline of demand for pharmaceutical distribution services.
• Expansion of Specialty Pharmaceuticals and Biologics: This is arguably the most significant value driver in the industry. Specialty drugs, used to treat complex or rare diseases, represent a small fraction of total prescription volume (approximately 2%) but now account for over half of all pharmaceutical spending in the U.S..¹⁰ These high-cost therapies require specialized handling, such as temperature-controlled “cold chain” logistics, which can triple handling costs compared to conventional drugs.¹⁰ This complexity allows distributors to offer higher-margin, value-added services, shifting the industry’s profit mix toward these products. Cold-chain logistics is the fastest-growing service category within the distribution market.¹⁰
• Growth of E-commerce and Direct-to-Patient Models: The rise of e-pharmacies and mail-order services is fundamentally altering last-mile logistics. This trend is shifting the distribution model from large, bulk replenishment shipments to hospitals and pharmacies toward smaller, more frequent, and individually trackable parcel deliveries directly to patients’ homes, a model that plays to the strengths of distributors with sophisticated logistics capabilities.¹⁰

3.4 Regulatory Environment

The healthcare distribution industry operates within a highly regulated framework that significantly influences its structure and competitive dynamics.

• Drug Supply Chain Security Act (DSCSA): This landmark U.S. legislation, now fully implemented, mandates an electronic, interoperable system to track and trace prescription drugs as they move through the supply chain.¹⁶ Compliance requires substantial investment in technology and sophisticated data management systems. While these regulations impose significant costs, they also create a formidable barrier to entry. The capital and expertise required to build and maintain a DSCSA-compliant system are immense, effectively solidifying the market position of the large, established players. This regulatory complexity functions as a competitive moat, protecting the “Big Three” from smaller competitors and potential new entrants, including technology giants like Amazon, who may excel at general logistics but lack the specialized expertise to navigate the intricate regulatory landscape of pharmaceutical distribution.
• Inflation Reduction Act (IRA): Signed into law in August 2022, the IRA introduced significant changes to prescription drug pricing within Medicare, including direct price negotiation by the government and rebates for price increases that outpace inflation.²⁰ While the primary impact of these provisions falls on pharmaceutical manufacturers, there are potential downstream effects for distributors. Changes in drug pricing dynamics could influence purchasing patterns, inventory valuation, and the economics of both branded and generic drug distribution.

3.5 Supply Chain Dynamics Post-COVID

The COVID-19 pandemic served as a historic stress test for the global healthcare supply chain, exposing critical vulnerabilities related to geographic concentration and a “just-in-time” inventory philosophy.²¹ In response, the industry has undergone a paradigm shift, moving from a singular focus on cost efficiency to a more balanced approach that prioritizes resilience and visibility. Key evolutionary trends include:

• Diversification and Near-Shoring: Companies are actively reducing their reliance on single countries for critical supplies, particularly personal protective equipment (PPE), and are investing in expanding manufacturing capabilities in North America to create a more resilient supply base.¹⁵
• Increased Inventory Levels: The “just-in-time” model is being supplemented by a “just-in-case” strategy, with distributors and providers holding higher levels of safety stock for critical items to buffer against future disruptions.²²
• Investment in Technology and Visibility: There is a heightened focus on deploying advanced technologies, such as predictive analytics, AI, and supply chain visibility platforms (e.g., Kinaxis, FourKites), to better forecast demand, anticipate potential disruptions, and enable more agile responses.²³

4.0 Competitive Landscape & Positioning

4.1 The “Big Three” Oligopoly

The U.S. healthcare distribution market is a highly concentrated industry, effectively functioning as an oligopoly dominated by three major players: Cardinal Health, McKesson Corporation (MCK), and Cencora, Inc. (COR), formerly AmerisourceBergen. These three companies collectively control an estimated 90% to 96% of the U.S. pharmaceutical wholesale market by revenue, creating an environment with high barriers to entry and intense, but rational, competition.¹⁴

• Pharmaceutical Segment Competition: In its largest business, Cardinal Health’s primary national competitors are McKesson and Cencora. The competition is based on scale, efficiency, service levels, and pricing.²⁶
• Medical Segment Competition: In the distribution of medical products, the competitive set is slightly broader and includes McKesson, Owens & Minor, Inc., and the privately held Medline Industries, Inc..²⁶

4.2 Cardinal Health’s Competitive Advantages (Moats)

Cardinal Health’s durable competitive position is protected by several powerful economic moats that are characteristic of the industry leaders:

• Scale and Network Effects: The company’s vast and highly efficient distribution network provides significant economies of scale, allowing it to operate on thin margins that are unattainable for smaller competitors. This scale creates a virtuous cycle: as more manufacturers and providers utilize the network, its efficiency increases, and its value to all participants grows.
• Regulatory Moat: As detailed previously, the complex and costly compliance requirements of the Drug Supply Chain Security Act (DSCSA) create a significant barrier to entry, protecting the incumbent “Big Three” from new market entrants.¹⁶
• High Customer Switching Costs: Cardinal Health is deeply integrated into the operational workflows of its customers. Its systems for ordering, inventory management, and logistics are embedded within thousands of hospitals and pharmacies. The cost, complexity, and operational risk associated with switching to a different primary distributor are substantial, leading to sticky customer relationships.

4.3 Differentiation Strategies

While all members of the “Big Three” benefit from similar scale-based advantages, Cardinal Health has pursued specific strategies to differentiate itself and capture additional value across the healthcare chain:

• Proprietary Medical Products: Unlike some competitors who are purely distributors, Cardinal Health manufactures a portfolio of its own Cardinal Health™ Brand medical products. This vertical integration into manufacturing provides a potential margin advantage compared to simply distributing third-party national brand products and is a key focus of the GMPD segment’s improvement plan.¹
• Vertical Integration into Specialty Services: The company’s most significant strategic differentiator is its aggressive expansion into high-value services for specialty physician practices. Through the acquisition of Management Services Organizations (MSOs) like Specialty Networks, GI Alliance, and Solaris Health, Cardinal Health is moving beyond logistics to provide a comprehensive suite of solutions, including practice management, data analytics, and clinical expertise. This creates a deeply integrated and sticky ecosystem that is difficult for competitors to replicate.¹

4.4 Threat from New Entrants

The potential entry of Amazon into pharmaceutical distribution has been a persistent concern for investors for several years. However, the threat has yet to materialize in a meaningful way. This is largely attributable to the formidable moats protecting the incumbents. Amazon’s core competencies in general logistics do not easily translate to the highly regulated, clinically complex, and relationship-driven world of pharmaceutical distribution, which involves navigating the DSCSA, managing complex reimbursement schemes, and handling specialized products like controlled substances and cold-chain biologics.

4.5 Vertical Integration Trends

The healthcare industry is undergoing a significant wave of vertical integration. Pharmacy Benefit Managers (PBMs) have merged with insurance companies (e.g., CVS/Aetna) and pharmacy chains. In response, distributors are moving downstream to capture more of the value chain. They have established Pharmacy Services Administrative Organizations (PSAOs) to manage relationships between PBMs and independent pharmacies, and are now, led by Cardinal Health, acquiring MSOs to integrate with physician practices.²⁵ Cardinal Health’s MSO strategy is a direct and aggressive move to secure its position in the most profitable and fastest-growing segment of the market: provider-administered specialty drugs.

Table 1: Competitive Snapshot (FY2025 Data)

Metric	Cardinal Health (CAH)	McKesson (MCK)	Cencora (COR)
Revenue (LTM)	$222.6B	$359.1B	$294.0B
Market Cap	$36.7B	$87.4B	$56.7B
Operating Margin (LTM)	1.1%	1.3%	1.1%
P/E Ratio (LTM)	23.9x	28.0x	30.1x
EV/EBITDA (LTM)	12.5x	15.1x	13.3x
Dividend Yield	1.4%	0.4%	0.7%

Sources: ³

Note: Data as of latest available filings and market data from late FY2025. LTM = Last Twelve Months.

5.0 Financial Performance & Metrics Analysis

5.1 Revenue Growth Trends

Cardinal Health has demonstrated a consistent ability to grow its top line over the past several years, driven primarily by the non-discretionary demand for pharmaceuticals. Total annual revenue increased from $136.8 billion in FY18 to a peak of $226.8 billion in FY24 before settling at $222.6 billion in FY25.³³ The modest 1.9% year-over-year decline in FY25 was entirely attributable to the previously disclosed expiration of a large contract with OptumRx. Excluding this non-recurring event, underlying revenue grew by a robust 18%, showcasing the strong fundamental demand across the business.³

• Pharmaceutical and Specialty Solutions: As the company’s largest segment, its performance dictates the overall revenue trajectory. The segment has benefited from price inflation on branded drugs and strong growth in high-value specialty pharmaceuticals. Despite the OptumRx headwind, the segment delivered impressive profit growth of 12% in FY25, reaching $2.3 billion.²
• Global Medical Products and Distribution (GMPD): This segment has been the focus of a significant turnaround. After struggling with performance issues that led to a $2.1 billion goodwill impairment charge in FY22, the “Medical Improvement Plan” has yielded substantial results.⁹ The segment successfully returned to profitability, achieving $135 million in segment profit in FY25 and generating positive cash flow. This turnaround was driven by disciplined inflation mitigation and cost optimization initiatives.¹
• Other: The newly reported “Other” segment is demonstrating its strategic importance as a growth driver. For FY25, the businesses within this category collectively achieved segment profit growth of 22%.² Quarterly results showed accelerating momentum, with revenue up 37% in the fourth quarter, driven by strong performance across at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics.³

5.2 Profitability Metrics

As a distributor, Cardinal Health operates on razor-thin margins, where incremental improvements can have a significant impact on bottom-line profitability. For the last twelve months, the company’s gross margin was 3.67%, its operating margin was 1.12%, and its net profit margin was 0.70%.³⁶ The more telling story, however, is the trajectory of profit growth. Non-GAAP operating earnings grew 15% in FY25 to $2.8 billion.³ This translated into strong bottom-line performance, with non-GAAP diluted EPS increasing 9% year-over-year to $8.24, up from $7.53 in FY24.²

5.3 Return Metrics (ROA, ROE, ROIC)

An analysis of Cardinal Health’s return metrics reveals a nuanced picture. The company’s normalized return on assets (ROA) is a solid 4.19%, generally in line with its peer Cencora (4.13%).²⁹ The normalized return on invested capital (ROIC) is exceptionally strong at 53.55%, indicating highly efficient capital deployment within its core operating model.²⁹

However, traditional metrics based on book value, such as return on equity (ROE), are not meaningful for analyzing Cardinal Health. The company’s balance sheet shows negative total shareholder equity of approximately -$2.6 billion.³⁶ This is not a sign of financial distress or insolvency but rather an accounting anomaly. It is the direct result of a long and consistent history of aggressive share repurchase programs, where the company has bought back stock at market prices well above its book value, thereby reducing the equity account over time. This practice is common for mature, highly cash-generative companies that prioritize returning capital to shareholders. Consequently, any analysis of Cardinal Health must disregard book value-based metrics and focus instead on earnings and cash flow-based measures of performance and valuation.

5.4 Working Capital Management

Efficient working capital management is the lifeblood of a distribution business. Cardinal Health operates with negative working capital of approximately -$2.5 billion.³⁶ This is a sign of operational strength, not weakness. It indicates that the company is effectively using its trade payables to suppliers to finance its inventory and accounts receivable. The ability to manage the cash conversion cycle—the time it takes to convert inventory into cash—is a critical driver of free cash flow generation.

5.5 Debt & Financial Flexibility

Cardinal Health maintains a solid balance sheet and ample financial flexibility. As of the most recent reporting, the company had total debt of approximately $9.4 billion and cash and equivalents of $3.9 billion, resulting in a net debt position of $5.5 billion.³⁶ The company’s debt is well-covered by its earnings, with a strong interest coverage ratio of over 10x.²⁹ Management has a stated commitment to maintaining its investment-grade credit rating, which provides access to capital at favorable rates and supports its disciplined framework for capital allocation.³⁸

Table 2: 7-Year Financial Summary (FY2019-FY2025)

(USD in millions, except EPS)	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total Revenue	$145,530	$152,920	$162,470	$181,330	$204,980	$226,830	$222,580
Gross Profit	$6,778	$6,545	$6,889	$7,414	$8,168	$8,170
Gross Margin %	4.7%	4.3%	4.2%	4.1%	4.0%	3.6%
Non-GAAP Operating Income	$2,353	$1,794	$1,664	$2,000	$2,130	$2,400	$2,800
Non-GAAP Op. Margin %	1.6%	1.2%	1.0%	1.1%	1.0%	1.1%	1.3%
Non-GAAP Net Income	$1,600	$1,638	$1,550	$1,340	$1,430	$1,900	$2,000
Non-GAAP Diluted EPS	$5.27	$5.57	$5.57	$5.06	$5.79	$7.53	$8.24
Operating Cash Flow	$2,722	$1,960	$2,429	$3,175	$2,844	$3,762	$2,400
Free Cash Flow (OpCF – CapEx)	$2,272	$1,560	$1,979	$2,725	$2,394	$3,262	$1,850

Sources: ¹

Note: Data compiled and reconciled from multiple annual reports and financial data providers. Non-GAAP figures are used for operating income, net income, and EPS to provide a clearer view of underlying operational performance, excluding litigation charges, impairments, and other special items.

6.0 Recent Challenges & Major Changes (2022-2024)

The period between 2022 and 2024 was transformative for Cardinal Health, defined by the resolution of legacy challenges and a strategic response to unprecedented macroeconomic and operational pressures.

6.1 Opioid Litigation Settlements

For nearly a decade, the most significant challenge and valuation overhang for Cardinal Health and its peers was the massive uncertainty surrounding their liability in the national opioid crisis. This uncertainty was largely resolved through a comprehensive settlement agreement.

• Financial Resolution: In February 2022, a global settlement agreement became effective between the “Big Three” distributors, Johnson & Johnson, and the vast majority of U.S. states and litigating political subdivisions.⁴¹ Under this agreement, Cardinal Health is obligated to pay up to $6.4 billion over an 18-year period.⁴² While this is a substantial sum, its long duration makes the annual cash flow impact manageable. More importantly, it converted a potentially catastrophic, unquantifiable legal risk into a known, predictable, and long-term liability. This de-risking of the balance sheet and future earnings was a profoundly positive catalyst for the stock, allowing investors to refocus on the company’s fundamental operating performance.
• Operational Changes: The settlement also mandated court-ordered injunctive relief for a period of ten years.⁴³ These terms require enhanced and standardized programs for monitoring, detecting, and reporting suspicious orders of controlled substances. A key component is the creation of a third-party “Clearinghouse” that will aggregate and analyze ordering data from all three distributors, providing unprecedented visibility into the flow of controlled substances.⁴³ While these measures add to operational complexity and compliance costs, they also further entrench the position of the “Big Three” by creating a standardized, high-cost compliance framework that would be exceptionally difficult for any new entrant to replicate.

6.2 COVID-19 Effects & Recovery Trajectory

The COVID-19 pandemic triggered the most severe disruption to the healthcare supply chain in modern history.

• Initial Shock and Response: In early 2020, Cardinal Health faced an unprecedented surge in demand for PPE, with requirements soaring to as much as 12 times the available supply.¹⁵ This was compounded by manufacturing shutdowns and logistical chaos, particularly from concentrated supply sources in China. The company’s response was multifaceted, involving a rapid pivot to diversify its global sourcing, expand its own North American manufacturing capacity for masks and gowns, and leverage data analytics to identify COVID-19 hotspots and dynamically allocate scarce supplies to areas of greatest need.¹⁵
• Long-Term Strategic Shift: The pandemic catalyzed a permanent shift in the company’s supply chain strategy. The focus has moved from pure “just-in-time” efficiency to a more balanced model emphasizing resilience. This includes maintaining higher inventory levels of critical products, continuing to diversify the supplier base to reduce geographic concentration, and investing heavily in technology to improve end-to-end supply chain visibility.²²

6.3 Inflation Pressures and Pricing Dynamics

The post-pandemic period was marked by rampant global inflation, which had a particularly acute impact on Cardinal Health’s Medical segment. Soaring costs for raw materials, international freight, and domestic transportation severely compressed margins and were a primary driver of the segment’s poor performance and goodwill impairment in FY22.⁸ A central pillar of the subsequent “Medical Improvement Plan” has been the implementation of initiatives to mitigate these inflationary pressures, including cost optimization and pricing adjustments. Management successfully achieved its year-end inflation mitigation target in FY24, marking a critical milestone in the segment’s recovery.¹

6.4 Generic Drug Pricing and Biosimilar Trends

The generics program remains a critical profit driver for the Pharmaceutical segment, as distributors typically earn higher margins on generic drugs than on branded ones.¹⁹ However, this market is subject to persistent pricing pressure and deflation. The company’s ability to maintain a stable and profitable generics program is essential for the segment’s financial health.⁹ A significant emerging trend is the growth of biosimilars—lower-cost versions of complex biologic drugs. As more high-profile biologics lose patent protection, the biosimilar market is expected to expand rapidly. For distributors, biosimilars represent a favorable opportunity, as they often provide higher profit potential than their branded counterparts, creating a potential tailwind to help offset traditional generic price erosion.¹³

7.0 Growth Strategy & Opportunities

With legacy issues largely addressed, Cardinal Health’s management team is now squarely focused on a multi-faceted growth strategy designed to enhance profitability and drive long-term shareholder value. The strategy is centered on strengthening the core, continuing the medical turnaround, and, most importantly, aggressively expanding into higher-margin, faster-growing adjacencies.

7.1 Core Strategic Pillars

As articulated by management during its 2025 Investor Day and subsequent earnings calls, the company’s strategy rests on three primary pillars ³⁸:

1. Strengthening the Core: Continuing to invest in the foundational pharmaceutical distribution business to enhance efficiency, improve customer experience, and grow with the market.
2. Executing the GMPD Turnaround: Ensuring the Global Medical Products and Distribution segment achieves sustained profitable growth through its ongoing improvement plan.
3. Accelerating Growth: Prioritizing investment and expansion in the higher-margin businesses now grouped under “Other” and aggressively building out its specialty services platform.

7.2 M&A and Expansion into Specialty Services

The cornerstone of Cardinal Health’s forward-looking growth strategy is its deliberate and aggressive push into specialty physician services through a series of strategic acquisitions. This is not merely diversification; it is a calculated move to create a powerful, vertically integrated ecosystem in the most valuable segment of the pharmaceutical market.

• Key Acquisitions: In a relatively short period, the company has acquired or taken a majority stake in several leading Management Services Organizations (MSOs), including Specialty Networks (serving urology, gastroenterology, and rheumatology practices), Integrated Oncology Network (ION), GI Alliance (the nation’s largest independent gastroenterology practice), and Solaris Health (a leading urology MSO).¹
• Strategic Rationale and Flywheel Effect: These acquisitions move Cardinal Health far beyond the role of a traditional distributor. By controlling the practice management layer for thousands of specialty physicians, the company gains a significant competitive advantage. This creates a powerful flywheel:

1. Secure Distribution Channel: It secures a large, captive channel for the distribution of high-cost, high-margin specialty drugs, which are prescribed and administered in these very practices.
2. Enhanced Data and Insights: It provides unparalleled, real-time data on prescribing patterns, clinical pathways, and operational benchmarks, which can be used to improve its own services and provide value back to both physicians and manufacturing partners.
3. Sticky, Bundled Services: It allows Cardinal Health to offer an integrated suite of services—including drug distribution, GPO contracting, data analytics, and practice management support—that makes the physician’s practice more efficient and profitable. This transforms the customer relationship from a transactional one to a deeply embedded strategic partnership, creating extremely high switching costs.

This integrated ecosystem in the most profitable segment of the market represents a formidable competitive moat and is poised to be the primary driver of durable, high-margin growth for the foreseeable future.

7.3 Technology & Digital Investments

Cardinal Health is making significant investments in technology to bolster efficiency, enhance resilience, and improve the customer experience across its businesses.

• Supply Chain and Logistics: The company is investing in advanced automation and robotics in its new distribution centers and is deploying sophisticated software platforms like Kinaxis and FourKites to enable predictive analytics, improve demand forecasting, and provide real-time visibility across the supply chain.⁸
• Customer-Facing Platforms: The rollout of new digital tools, such as the Vantus HQ customer ordering platform, is aimed at simplifying interactions and improving service levels for its pharmacy and provider customers.⁴⁹

7.4 Medical Segment (GMPD) Expansion Plans

The strategy for the now-stabilized GMPD segment is focused on profitable growth. The key initiatives are to accelerate sales of higher-margin Cardinal Health™ Brand products and to continue driving simplification and cost optimization throughout the segment’s operations.¹ The long-term target is to generate over $50 million in additional profit per year from this segment after fiscal 2026.⁴⁷

7.5 Growth in “Other” Businesses

The company is actively investing to capitalize on the favorable long-term trends supporting its newly highlighted “Other” businesses.

• at-Home Solutions: The growing demand for healthcare in the home is a powerful secular tailwind. Cardinal Health is expanding its distribution network to support this shift and has augmented its capabilities with the acquisition of Advanced Diabetes Supply Group.¹
• OptiFreight Logistics: The company is leveraging its scale and investing in technology-driven solutions like TotalVue™ Insights to continue its strong growth trajectory in managing logistics and transportation spend for healthcare providers.⁸

8.0 Capital Allocation Strategy

Cardinal Health employs a clear, disciplined, and shareholder-friendly capital allocation framework designed to balance reinvestment for growth with robust returns of capital to shareholders.

8.1 A Disciplined Framework

The company’s capital allocation priorities are explicitly defined and consistently communicated ³⁸:

1. Maintain an Investment-Grade Balance Sheet: The foundation of the strategy is a strong balance sheet, which provides financial flexibility and access to low-cost capital.
2. Invest in Organic Growth: Prioritize capital expenditures (CapEx) that support organic growth, such as building new, automated distribution centers and investing in technology.
3. Baseline Return of Capital: A commitment to returning capital to shareholders through a growing dividend and consistent share repurchases.
4. Disciplined Mergers & Acquisitions (M&A): Actively pursue strategic, targeted acquisitions that align with the growth strategy, particularly in the specialty and at-home markets.
5. Opportunistic Share Repurchases: Utilize excess free cash flow for additional, opportunistic share buybacks to further enhance shareholder returns.

8.2 Dividend Policy and Sustainability

Cardinal Health has a long and consistent history of paying a quarterly dividend.⁵⁰ The current annual dividend of $2.04 per share provides a yield of approximately 1.4%.³⁶ The dividend is well-covered by earnings, with a conservative payout ratio of just 31.5% of non-GAAP earnings, indicating that the dividend is highly sustainable and has ample room for future growth.³⁶

8.3 Share Repurchase Programs

Share repurchases are a significant component of the company’s capital return strategy. Management has guided to approximately $750 million in share repurchases for FY26.³ These buybacks have consistently reduced the number of shares outstanding, providing a meaningful, recurring tailwind to earnings per share (EPS) growth.³

8.4 Capital Expenditure Priorities

Capital expenditures are focused on enhancing operational efficiency and supporting organic growth. Recent investments have been directed toward the construction of new, state-of-the-art distribution facilities featuring advanced automation and robotics, as well as investments in digital platforms and supply chain technology.⁸ The company has guided for approximately $600 million in CapEx for FY26.³

8.5 M&A Strategy and Integration

As detailed in the growth strategy, the company’s M&A focus is squarely on acquiring high-growth, margin-accretive businesses in the specialty services and at-home healthcare markets. The financing for these acquisitions has led to a near-term increase in interest expense, which is factored into the company’s financial guidance.³ The successful integration of these new businesses is a key priority for management.

8.6 Free Cash Flow Generation and Utilization

Underpinning the entire capital allocation strategy is the company’s robust ability to generate free cash flow (FCF). In FY25, Cardinal Health generated $2.5 billion in adjusted FCF.³ For FY26, management has provided strong guidance for adjusted FCF in the range of $2.75 billion to $3.25 billion.⁴ This substantial and predictable cash generation provides the necessary resources to simultaneously fund organic investments, strategic acquisitions, dividends, and share repurchases.

9.0 Risk Assessment

While the investment thesis for Cardinal Health is compelling, it is essential to consider the key risks that could impede the company’s performance and negatively impact shareholder returns.

9.1 Business and Operational Risks

• Margin Pressure in Core Distribution: The foundational pharmaceutical distribution business operates in a highly competitive environment and is subject to continuous pricing pressure from its largest customers during contract renewals. Furthermore, deflation in generic drug prices, while recently stable, remains a potential headwind that could compress margins.⁵
• Execution Risk: The company’s future success is heavily dependent on the continued successful execution of its strategic plans. This includes sustaining the profitable growth of the GMPD segment and avoiding any operational setbacks that could reverse its recent progress. Additionally, the successful integration of several large and complex acquisitions, such as GI Alliance and Solaris Health, is critical to realizing their expected financial benefits.
• Supply Chain Vulnerability: Despite significant investments in building a more resilient supply chain, the company remains exposed to the risk of global disruptions. Geopolitical conflicts, trade disputes, pandemics, or natural disasters could interrupt the flow of products, increase transportation costs, and negatively impact operations.¹⁶

9.2 Regulatory and Legal Risks

• Ongoing Litigation: Although the global opioid settlement has resolved the vast majority of claims, Cardinal Health is not entirely free from legal risk. The company may still face litigation from non-participating entities or other legal challenges related to its historical distribution of controlled substances.⁴²
• Healthcare Policy and Reimbursement Changes: The U.S. healthcare system is subject to ongoing political and regulatory scrutiny. Future legislation related to drug pricing, reimbursement models, or supply chain regulation could have an adverse effect on the company’s business model and profitability.²⁰

9.3 Customer Concentration and Dependency

A significant portion of Cardinal Health’s revenue is derived from a small number of very large customers, including major retail pharmacy chains and hospital GPOs. The loss of a key customer, or the negotiation of significantly less favorable contract terms, could have a material negative impact on revenue and profitability, as demonstrated by the loss of the OptumRx contract.¹²

9.4 Economic Sensitivity and Recession Resilience

While the healthcare sector is broadly considered defensive, Cardinal Health is not entirely immune to macroeconomic cycles. A severe economic downturn could lead to higher unemployment and a loss of commercial health insurance, potentially reducing demand for prescription drugs. Furthermore, a recession could cause patients to defer elective surgical procedures, which would negatively impact volumes and profitability in the GMPD segment.

10.0 Valuation Analysis

The valuation of Cardinal Health suggests a compelling opportunity, with the current market price not fully reflecting the company’s improved risk profile and enhanced earnings growth trajectory. The analysis is based on a combination of historical multiples, peer comparisons, and forward-looking cash flow considerations.

10.1 Current Trading Multiples vs. Historical Ranges

Cardinal Health’s valuation relative to its own history is complex due to the impact of litigation charges and impairments on historical GAAP earnings, which have caused extreme volatility in its trailing P/E ratio.⁵² As of September 2025, the trailing P/E ratio stood at approximately 23x.⁵² A more normalized view shows the P/E ratio is trading below its 10-year historical average of approximately 35x, but this average is skewed by outlier periods.⁵² On a forward-looking basis, given the company’s guidance for 13-15% EPS growth in FY26, the implied forward P/E multiple is significantly more attractive. The LTM EV/EBITDA multiple of approximately 12.5x is reasonable for a stable, cash-generative business in the sector.³⁰

10.2 Peer Group Valuation Comparison

Compared to its direct competitors, Cardinal Health trades at a valuation that is broadly in line, suggesting the market has not yet awarded it a premium for its differentiated growth strategy. Its normalized LTM P/E ratio of approximately 18x is comparable to Cencora (~19x) and slightly below McKesson (~21x).²⁹ The company’s Price/Sales ratio of 0.16x is lower than both McKesson (0.23x) and Cencora (0.18x), which is reflective of its historically lower overall profit margins but also indicates potential for re-rating as the margin profile improves.²⁹

10.3 Discounted Cash Flow (DCF) Considerations

A DCF analysis is a cornerstone of the valuation, given the company’s strong and predictable cash flow generation. Key inputs for a DCF model would include:

• Free Cash Flow Projections: The starting point would be management’s robust FY26 adjusted FCF guidance of $2.75 billion to $3.25 billion.⁴
• Growth Assumptions: Mid-term growth would be modeled in line with management’s 12-14% non-GAAP EPS CAGR target for FY26-FY28, with growth gradually tapering to a terminal rate of 2.0-2.5%, consistent with long-term economic growth.⁴⁷
• Discount Rate (WACC): A weighted average cost of capital would be calculated using the company’s low beta (approximately 0.74, indicating lower volatility than the broader market), its current cost of debt, and its market-based capital structure.³⁶

10.4 Dividend Yield Attractiveness

The current dividend yield of approximately 1.4% provides a modest but secure income component to the total return proposition.²⁹ While not high enough to attract pure income-focused investors, its stability and potential for growth contribute to the stock’s defensive characteristics.

10.5 Factors Supporting Multiple Expansion

Several key factors could drive a positive re-rating of Cardinal Health’s valuation multiples over the investment horizon:

• Sustained Execution: Consistently meeting or exceeding its double-digit EPS growth targets will build credibility with investors and justify a higher multiple.
• Margin Improvement: Demonstrable and sustained margin expansion in the GMPD segment and a growing profit contribution from the higher-margin “Other” and specialty businesses will change the narrative around the company’s overall profitability.
• De-risking and Strategic Clarity: The market’s continued digestion of the opioid settlement’s finality, combined with the strategic clarity provided by the new reporting structure, should reduce the perceived risk and warrant a higher valuation.

Table 3: Valuation Multiples Comparison (Historical & Peer Group)

Metric	Cardinal Health (Current)	CAH (5-Yr Avg)	McKesson (Current)	Cencora (Current)
P/E (Forward)	~11.5x – 12.0x	~12.5x	~14.0x	~14.5x
EV/EBITDA (Forward)	~10.0x	~9.5x	~11.5x	~11.0x
P/S (LTM)	0.16x	0.12x	0.23x	0.18x
Dividend Yield %	1.4%	2.5%	0.4%	0.7%

Sources: ²⁹ and analyst estimates.

Note: Forward multiples are estimated based on FY26 consensus estimates. 5-Yr Avg P/E is based on normalized earnings. 5-Yr Avg Dividend Yield is higher due to lower historical stock price.

11.0 Management Assessment

11.1 Leadership Team and Strategic Vision

The current management team, led by CEO Jason Hollar, has been instrumental in the company’s recent operational and strategic turnaround.

• CEO Jason Hollar: Appointed CEO in September 2022 after joining as CFO in 2020, Mr. Hollar brought extensive experience in finance and operations from his time as CFO at Tenneco and Sears.⁵⁷ Since taking the helm, he has driven a clear strategic agenda focused on simplification, prioritization, and disciplined execution. His leadership has coincided with a significant positive inflection in the company’s financial performance, service levels, and stock price.⁵⁷
• Strategic Vision: The vision articulated by Hollar and his team is clear and logical: strengthen the core distribution business while aggressively investing in the higher-growth, higher-margin areas of specialty services and at-home care. The reorganization of the company’s reporting structure is a direct reflection of this transparent and focused strategy.
• Experienced Operating Committee: Hollar is supported by an experienced team of executives leading the key business units, including Debbie Weitzman as CEO of the Pharmaceutical and Specialty Solutions Segment and Steve Mason as CEO of the Global Medical Products and Distribution segment, both of whom are long-tenured leaders within Cardinal Health.⁵⁸

11.2 Capital Allocation Discipline

The management team has demonstrated a highly disciplined and shareholder-friendly approach to capital allocation. They have successfully balanced significant strategic M&A to fuel future growth with a consistent and substantial return of capital to shareholders through both dividends and share repurchases.³⁸ This balanced approach is a hallmark of a mature and well-managed enterprise.

11.3 Operational Execution

Perhaps the strongest testament to the current management team’s capability is the successful execution of the GMPD Improvement Plan. Turning around a business of that scale, particularly in the face of severe inflationary and supply chain pressures, required exceptional operational rigor. The fact that the segment has returned to sustained profitability and positive cash flow is a major credit to the team’s execution capabilities.¹

11.4 Communication Transparency and Guidance Reliability

Management’s communication with the investment community has been transparent and credible. The 2025 Investor Day provided a clear and detailed roadmap for the company’s long-term strategy and financial targets.⁴⁷ Furthermore, the company has established a track record of reliability, having raised its financial guidance multiple times throughout fiscal 2025, demonstrating both confidence in the business and a commitment to under-promising and over-delivering.³

12.0 Key Catalysts & Monitoring Points

Investors should monitor several key developments and metrics that could serve as catalysts to validate the investment thesis and drive share price performance.

• GMPD Segment Profitability: A primary catalyst will be the continued margin expansion and profit growth in the GMPD segment. Investors should monitor the company’s progress toward its long-term target of generating at least $50 million of incremental profit growth per year after fiscal 2026.⁴⁷
• Growth in “Other” and Specialty: The performance of the high-growth businesses is critical. Tracking the revenue and profit growth of the at-Home, NPHS, and OptiFreight businesses against their long-term normalized growth target of approximately 10% will be key.⁴⁷ Evidence of successful integration and margin accretion from the recent MSO acquisitions will be a significant positive indicator.
• Free Cash Flow Generation: The company’s ability to meet or exceed its robust FY26 adjusted free cash flow guidance of $2.75 billion to $3.25 billion is fundamental to the thesis, as this cash flow underpins all capital allocation activities.⁴ Any upside to this guidance would be a strong positive catalyst.
• Regulatory Environment: While no major changes are anticipated, investors should monitor any developments related to the Inflation Reduction Act’s drug pricing negotiations to assess any potential downstream impact on distributor economics.²⁰
• Capital Deployment: Continued execution of the share repurchase program and any future value-enhancing, bolt-on acquisitions in the specialty or at-home space would further validate management’s disciplined capital allocation strategy.

13.0 Investment Thesis Considerations

The investment case for Cardinal Health can be framed through a series of probability-weighted scenarios, culminating in a base case that supports a favorable risk/reward profile.

13.1 Bull Case Scenario

In a bull case scenario, Cardinal Health executes flawlessly on its strategic initiatives. The GMPD segment’s margin recovery and profit growth accelerate beyond current expectations, driven by strong Cardinal Health™ Brand sales and further cost efficiencies. The recently acquired MSOs are integrated seamlessly, and the company realizes significant revenue and cost synergies, driving the “Other” and Specialty businesses to high-teens growth and substantial margin accretion. This clear demonstration of a successful transformation into a higher-growth, higher-margin healthcare services company leads the market to award the stock a premium valuation, with the forward P/E multiple expanding to the 18x-20x range. This would result in sustained annual EPS growth above 15% and significant share price outperformance relative to the market and peers.

13.2 Bear Case Scenario

The bear case scenario envisions a failure to execute on key strategic priorities. Renewed and intense pricing pressure from large pharmaceutical distribution customers erodes the margins in the core business, offsetting gains elsewhere. The GMPD turnaround stalls or reverses due to unforeseen macroeconomic pressures or internal execution missteps. The integration of the large MSO acquisitions proves to be more challenging and less accretive than anticipated, leading to goodwill write-downs and a failure to deliver on growth promises. In this scenario, EPS growth would decelerate to the low-single-digit range, the growth narrative would be invalidated, and the stock would likely de-rate, remaining range-bound or declining.

13.3 Base Case & Probability-Weighted Outcome

The base case, which underpins the BUY recommendation, assumes that management continues to execute effectively on its stated strategy. The company successfully achieves its long-term non-GAAP diluted EPS CAGR target of 12% to 14% for the FY26-FY28 period.⁴⁷ This growth is driven by stable, low-single-digit profit growth in the core pharma business, steady and modest improvement in the GMPD segment, and strong, double-digit growth from the specialty services and “Other” business segments. The company continues its disciplined capital allocation, using its robust free cash flow to fund growth and return capital to shareholders. As the market gains confidence in the sustainability of this new, higher-growth algorithm and the de-risked profile of the company, the stock price appreciates in line with its strong earnings growth, with the potential for modest multiple expansion toward a 14x-16x forward P/E multiple.

13.4 Time Horizon Considerations

The investment thesis is predicated on a medium-term time horizon of two to three years. This timeframe is sufficient to allow for the full financial benefits of the GMPD improvement plan to be realized and for the successful integration of the recent strategic acquisitions to be demonstrated in the company’s reported financial results and forward-looking guidance. It also allows time for the market to fully recognize and re-rate the company based on its transformed business mix and enhanced growth profile.

Frequently Asked Questions

Earnings & Business Model

• Are earnings at a cyclical high or cyclical low? Earnings are in a strong growth phase rather than at a cyclical peak or low. The company delivered 9% non-GAAP diluted EPS growth in fiscal year 2025 and has guided for accelerated growth of 13% to 15% in fiscal year 2026. Furthermore, management has confirmed a long-term target of 12% to 14% non-GAAP diluted EPS compound annual growth from fiscal 2026 to 2028, indicating expectations of sustained momentum.  
• Are earnings driven primarily by the external environment or internal company actions? Earnings are driven by a combination of both, but recent outperformance has been significantly influenced by internal strategic actions. While the company benefits from the resilient external demand for healthcare products, its earnings growth is being propelled by the successful execution of its Medical Improvement Plan, which returned the Global Medical Products and Distribution (GMPD) segment to profitability, and a series of strategic acquisitions in the high-margin specialty physician services sector.  
• Can this business be easily understood? The core business is straightforward: it acts as a critical intermediary distributing pharmaceuticals and medical products from manufacturers to providers like hospitals and pharmacies. However, the business has layers of complexity due to its immense scale, thin profit margins, a stringent regulatory environment, and its strategic expansion into more nuanced, higher-margin service businesses. The company’s recent reorganization of its reporting segments was specifically designed to provide greater transparency and make the performance of its distinct business units easier to understand.  
• Can this company be undermined by foreign, low-cost labor? The core distribution business, which is primarily logistics and service-based within the U.S., is largely insulated from this risk. The Medical segment, which involves global sourcing and manufacturing of its own branded products, does have exposure to global supply chains. However, in response to pandemic-era disruptions, the company has been actively working to mitigate this risk by diversifying its sourcing and expanding its North American manufacturing capabilities.  
• Do brands matter in the business? Or is this a commodity producer? The business is a hybrid. In its role as a distributor, the service has commodity-like aspects where scale and efficiency are paramount. However, in its Medical segment, the company actively manufactures and promotes its own “Cardinal Health™ Brand” products, which are a key component of its strategy to improve profitability. Therefore, while it distributes commodity generics, it is not purely a commodity producer and leverages its own brand to create value.  

Financial Health & Accounting

• Does the company have assets that are not fully recognized in the balance sheet? Yes. The company’s most significant economic assets are intangible and not fully captured on the balance sheet. These include its vast and efficient distribution network, deeply integrated customer relationships with high switching costs, and the formidable regulatory moat created by its compliance infrastructure. The balance sheet also shows negative shareholder equity due to a long history of share repurchases, which can obscure the true economic value of the enterprise.  
• Has the company recently changed accounting policies? The company has not changed its fundamental accounting policies. However, it did implement a significant change to its financial reporting structure effective January 1, 2024. It realigned its business into a new segment structure to provide greater visibility into its core and growth businesses.  
• How conservative is the company’s accounting? Are they over- or under-stating earnings? The company’s accounting appears to be standard and transparent for a large public corporation. It reports both GAAP and non-GAAP financial measures, providing detailed reconciliations between the two. This common practice allows investors to see underlying operational performance by excluding items like litigation charges and acquisition-related costs. There are no apparent red flags to suggest earnings are being artificially inflated or suppressed.  
• Is net income diverging from cash from operations? No, cash from operations is stronger than net income, which is a sign of healthy earnings quality. In fiscal year 2025, the company generated $2.4 billion in operating cash flow, significantly higher than its net income of $1.56 billion.  

Profitability & Capital

• How profitable is this business? What is the return on capital invested? Return on equity? As a distributor, Cardinal Health operates on thin margins; its LTM net profit margin was 0.70%. However, the business is highly efficient with its capital.
  • Return on Invested Capital (ROIC): The company’s normalized ROIC is an exceptionally strong 53.55%, indicating highly effective capital deployment in its core operations.  
  • Return on Equity (ROE): ROE is not a meaningful metric for Cardinal Health because the company has negative shareholder equity on its balance sheet. This is an accounting result of its long-standing practice of buying back shares and is not an indicator of financial distress.  
• How much free cash flow does the business generate? How does management use this free cash flow? What is their philosophy? The company is a strong generator of free cash flow (FCF). It generated $2.5 billion in adjusted FCF in fiscal 2025 and has guided for $2.75 billion to $3.25 billion in fiscal 2026. Management follows a disciplined capital allocation framework with the following priorities: maintaining a strong balance sheet, investing in organic growth, returning capital to shareholders via dividends and buybacks, and pursuing strategic M&A.  
• How CapEx hungry is this business? What % of cash from operations must be spent on CapEx to sustain the business? The business is not overly capital-intensive. In fiscal 2025, capital expenditures of $547 million represented about 23% of operating cash flow. For fiscal 2026, guided CapEx of ~$600 million is expected to be approximately 16% to 18% of projected operating cash flow. These investments are primarily for growth and efficiency, such as building new automated distribution centers.  

Shareholder & Management Topics

• Is the company buying back shares? Paying dividends? Yes, the company does both consistently. It has a long history of paying a quarterly dividend and actively repurchases shares as a core part of its capital return strategy. The company guided to approximately $750 million in share repurchases for fiscal 2026.  
• Does the company issue large amounts of new shares to insiders? No. The company is a net repurchaser of its stock, with the number of shares outstanding decreasing over the past year. While executives receive stock and options as a significant part of their compensation, these issuances are more than offset by the company’s share buyback programs.  
• How many options / shares is the management issuing to insiders? Is it more than 10% of net income? The value of stock awards to the top five executives in fiscal 2024 was approximately 4.5% of that year’s net income, which is well below the 10% threshold.  
• What are the motivations of management? Do they own a lot of stock and options? Management’s stated motivation is to create long-term shareholder value through the execution of its strategic priorities. Their financial interests are aligned with shareholders through an executive compensation program that is heavily weighted toward performance-based stock awards. While direct insider stock ownership is low at 0.07%, which is common for a company of this size, their compensation structure ensures a strong link to company performance.  
• What is the compensation policy of directors and management? The compensation policy, detailed in the company’s proxy statement, is designed to link pay with performance. It includes a mix of base salary, an annual cash bonus tied to specific financial and strategic goals, and long-term equity incentives (like Performance Share Units) that are tied to metrics such as total shareholder return.  
• Is the stock and ADR? What are the ADR fees? The stock is common stock, not an American Depositary Receipt (ADR). It trades on the New York Stock Exchange (NYSE) under the ticker symbol CAH. As such, there are no ADR fees.  

Industry & Market

• How profitable is this industry? Are there a lot of competitors? What are the barriers to entry? The healthcare distribution industry is characterized by very low profit margins. It is a highly concentrated market, with Cardinal Health, McKesson, and Cencora (the “Big Three”) controlling over 90% of the U.S. market. Barriers to entry are extremely high due to the immense scale required, deep customer integration creating high switching costs, and significant regulatory hurdles like the Drug Supply Chain Security Act (DSCSA).  
• Outlook for the company’s products and services? How big will this market be? Is it growing? Shrinking? Domestic or international? The outlook is positive. The global healthcare distribution market is valued at over $1.1 trillion and is projected to grow at a compound annual rate of approximately 7%. This growth is driven by durable trends like an aging population and the increasing use of high-value specialty drugs. North America is the largest market, and Cardinal Health’s business is primarily focused on the U.S..  
• Has the business environment changed recently? Yes, the environment has evolved significantly. Key changes include a strategic shift in supply chain management from cost-efficiency to resilience post-pandemic, persistent inflationary pressures, and new drug pricing regulations like the Inflation Reduction Act. In response, Cardinal Health has also changed, updating its reporting structure and accelerating its strategy to acquire specialty service providers.  

Recent Events & Risk

• Has the company made any significant acquisitions recently? Yes, this is a central part of its current growth strategy. In the past year, the company has announced or completed several key acquisitions to build its specialty physician services platform, including Integrated Oncology Network (ION), a majority stake in GI Alliance, Advanced Diabetes Supply Group, and most recently, Solaris Health.  
• Recent changes in the business, new markets, new production facilities, what’s changed recently? New management?
  • Business Changes: The company reorganized its reporting structure in January 2024 and is aggressively expanding into the specialty physician services market through acquisitions.  
  • New Facilities: Cardinal Health is investing in its network, recently opening a new Consumer Health Logistics Center in Ohio and a new at-Home Solutions distribution center in Texas.  
  • Management: Jason Hollar was appointed CEO in September 2022, and Val Pitteroff was named the new Chief Human Resources Officer in September 2025.  
• What are the recent news on the company? Recent news has been largely positive, highlighted by a strong earnings report for fiscal year 2025 and an increased financial outlook for fiscal 2026 (August 12, 2025). This was accompanied by the announcement of another strategic acquisition, Solaris Health, to bolster its urology services platform. The company also continues to announce operational expansions, such as new distribution centers.  
• What factors would cause the stock to decline? Are these factors controlled by the company or the external environment? Potential negative factors include a mix of internal and external risks.
  • Internal: A failure to execute on strategic plans, such as sustaining the turnaround of the Medical segment or poorly integrating its recent large acquisitions, could cause the stock to decline.  
  • External: Factors outside of the company’s direct control include renewed margin pressure from its large customers, significant price deflation for generic drugs, or unfavorable changes in government healthcare policy.  
• What is the risk of a catastrophic loss on this investment? What is the chance of a total loss? The risk of a total loss is exceptionally low. Cardinal Health is an integral part of the U.S. healthcare infrastructure and a Fortune 15 company with a resilient business model. The most significant existential risk the company faced, unquantified liability from opioid litigation, has been largely resolved through a multi-billion dollar, 18-year settlement, converting a catastrophic risk into a manageable long-term liability.  
• What off B/S liabilities does the company have? The company’s public filings do not indicate any unusual or significant off-balance sheet arrangements. Like most large corporations, it has standard operating leases for facilities and equipment, but no material liabilities that would not be apparent from a review of its financial statements.

Works cited

1. Cardinal Health Fiscal Year 2024 Annual Report and Form 10-K, accessed September 23, 2025, https://www.cardinalhealth.com/content/dam/corp/web/documents/Report/cardinal-health-FY24-annual-report.pdf
2. Annual report, accessed September 23, 2025, https://s201.q4cdn.com/566741227/files/doc_financials/2025/ar/CAH-2025-Annual-Report.pdf
3. Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance, accessed September 23, 2025, https://newsroom.cardinalhealth.com/2025-08-12-Cardinal-Health-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2026-Guidance
4. Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance – PR Newswire, accessed September 23, 2025, https://www.prnewswire.com/news-releases/cardinal-health-reports-fourth-quarter-and-fiscal-year-2025-results-and-raises-fiscal-year-2026-guidance-302527633.html
5. Fiscal 2019 Form 10-K – SEC.gov, accessed September 23, 2025, https://www.sec.gov/Archives/edgar/data/721371/000072137119000090/a19q4_10kx063019xform10-k.htm
6. Cardinal Health, Inc., accessed September 23, 2025, https://s201.q4cdn.com/566741227/files/doc_financials/2025/q4/af4f5ef3-12df-4c7e-a350-e1d952402ed5.pdf
7. Investor relations: Cardinal Health, Inc., accessed September 23, 2025, https://ir.cardinalhealth.com/overview/default.aspx
8. Cardinal Health Announces Progress on Business and Portfolio Review and Fiscal 2024 Outlook Update, accessed September 23, 2025, https://newsroom.cardinalhealth.com/2024-01-09-Cardinal-Health-Announces-Progress-on-Business-and-Portfolio-Review-and-Fiscal-2024-Outlook-Update
9. Cardinal Health FY22 annual report and Form 10-K, accessed September 23, 2025, https://www.cardinalhealth.com/content/dam/corp/web/documents/Report/cardinal-health-FY2022-annual-report-and-form-10K.pdf
10. Healthcare Distribution Market Size, Trends, Share Analysis 2025 …, accessed September 23, 2025, https://www.mordorintelligence.com/industry-reports/healthcare-distribution-market
11. Healthcare Distribution Market YoY Growth Rate, 2025-2032 – Coherent Market Insights, accessed September 23, 2025, https://www.coherentmarketinsights.com/industry-reports/healthcare-distribution-market
12. Cardinal Health, Inc., accessed September 23, 2025, https://s201.q4cdn.com/566741227/files/doc_financials/2025/q3/10-Q.pdf
13. Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook – May 1, 2025, accessed September 23, 2025, https://newsroom.cardinalhealth.com/2025-05-01-Cardinal-Health-Reports-Third-Quarter-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2025-Outlook
14. Drug Distribution Industry Trends for 2025 – Morningstar, accessed September 23, 2025, https://www.morningstar.com/stocks/drug-distribution-industry-trends-2025
15. How Cardinal Health pivoted its business during COVID-19 to improve its medical supply chain | Fierce Healthcare, accessed September 23, 2025, https://www.fiercehealthcare.com/hospitals/how-cardinal-health-pivoted-its-business-during-covid-19-to-improve-its-medical-supply
16. Healthcare Distribution Market Size, Share, Industry Forecast by 2032 – Emergen Research, accessed September 23, 2025, https://www.emergenresearch.com/industry-report/healthcare-distribution-market
17. Healthcare Distribution Market Size & Share Report, 2024 – 2032, accessed September 23, 2025, https://www.gminsights.com/industry-analysis/healthcare-distribution-market
18. Healthcare Distribution Market Report 2025, Size and Trends 2034, accessed September 23, 2025, https://www.thebusinessresearchcompany.com/report/healthcare-distribution-global-market-report
19. The Impact of Pharmaceutical Wholesalers on U.S. Drug Spending …, accessed September 23, 2025, https://www.commonwealthfund.org/publications/issue-briefs/2022/jul/impact-pharmaceutical-wholesalers-drug-spending
20. The Inflation Reduction Act: Drug pricing implementation progress – Cardinal Health, accessed September 23, 2025, https://www.cardinalhealth.com/en/services/specialty-physician-practice/resources/healthcare-policy/inflation-reduction-act.html
21. Expert insights on navigating 2022 healthcare supply chain trends – Cardinal Health, accessed September 23, 2025, https://www.cardinalhealth.com/en/solutions/medical-distribution/supply-chain-center/supply-chain-resiliency/navigating-2022-healthcare-supply-chain-trends.html
22. Latest articles | Cardinal Health Newsroom, accessed September 23, 2025, https://newsroom.cardinalhealth.com/2021-04-28-Pivoting-in-a-Pandemic
23. Supply chain management reimagined: | Cardinal Health, accessed September 23, 2025, https://www.cardinalhealth.com/content/dam/corp/web/documents/whitepaper/cardinal-health-supply-chain-management-reimagined.pdf
24. Supply chain management reimagined – Cardinal Health, accessed September 23, 2025, https://www.cardinalhealth.com/en/solutions/medical-distribution/supply-chain-center/optimizing-your-supply-chain/supply-chain-management-reimagined.html
25. Inside the 2025 PSAO Market: How Wholesalers … – Drug Channels, accessed September 23, 2025, https://www.drugchannels.net/2025/09/inside-2025-psao-market-how-wholesalers.html
26. Cardinal Health Inc Comparisons to its Competitors and Market Share – CSIMarket, accessed September 23, 2025, https://csimarket.com/stocks/compet_glance.php?code=CAH
27. Cardinal Health, Cencora, and McKesson Expand Buy-and-Bill Market Presence Through Vertical Integration – GeneOnline, accessed September 23, 2025, https://www.geneonline.com/cardinal-health-cencora-and-mckesson-expand-buy-and-bill-market-presence-through-vertical-integration/
28. Cardinal Health (CAH) Competitors and Alternatives 2025 – MarketBeat, accessed September 23, 2025, https://www.marketbeat.com/stocks/NYSE/CAH/competitors-and-alternatives/
29. CAH Stock Price Quote – Cardinal Health Inc – Morningstar, accessed September 23, 2025, https://www.morningstar.com/stocks/xnys/cah/quote
30. Cardinal Health – Public Comps and Valuation Multiples, accessed September 23, 2025, https://multiples.vc/public-comps/cardinal-health-valuation-multiples
31. McKesson – Public Comps and Valuation Multiples, accessed September 23, 2025, https://multiples.vc/public-comps/mckesson-valuation-multiples
32. Cencora – Public Comps and Valuation Multiples, accessed September 23, 2025, https://multiples.vc/public-comps/cencora-valuation-multiples
33. Cardinal Health Revenue 2016-2025 – Bullfincher.io, accessed September 23, 2025, https://bullfincher.io/companies/cardinal-health/revenue
34. Cardinal Health Annual Report and Shareholder Letter FY18, accessed September 23, 2025, https://www.cardinalhealth.com/content/dam/corp/web/documents/fact-sheet/cardinal-health-annual-report-and-shareholder-letter-FY18.pdf
35. Cardinal Health Revenue 2010-2025 | CAH – Macrotrends, accessed September 23, 2025, https://www.macrotrends.net/stocks/charts/CAH/cardinal-health/revenue
36. Cardinal Health (CAH) Statistics & Valuation – Stock Analysis, accessed September 23, 2025, https://stockanalysis.com/stocks/cah/statistics/
37. Cardinal Health (CAH) Balance Sheet & Financial Health Metrics – Simply Wall St, accessed September 23, 2025, https://simplywall.st/stocks/us/healthcare/nyse-cah/cardinal-health/health
38. Cardinal Health, Inc., accessed September 23, 2025, https://s201.q4cdn.com/566741227/files/doc_financials/2025/q2/Q2-FY25-Earnings-Presentation.pdf
39. Financial Statements – Cardinal Health Inc CAH – Morningstar, accessed September 23, 2025, https://www.morningstar.com/stocks/xnys/cah/financials
40. Cardinal Health Cash Flow from Operating Activities 2010-2025 | CAH – Macrotrends, accessed September 23, 2025, https://macrotrends.net/stocks/charts/CAH/cardinal-health/cash-flow-from-operating-activities
41. How do the 2022 national opioid settlements impact the NIPAs? | U.S. Bureau of Economic Analysis (BEA), accessed September 23, 2025, https://www.bea.gov/help/faq/1470
42. Distributors Announce Proposed Opioid Settlement Agreement …, accessed September 23, 2025, https://www.mckesson.com/about-us/newsroom/press-releases/2021/distributors-announce-proposed-opioid-settlement-agreement/
43. Proposed Opioid Litigation Comprehensive Settlement and Injunctive Relief Terms – February 25, 2022 – Cardinal Health, accessed September 23, 2025, https://www.cardinalhealth.com/content/dam/corp/web/documents/Report/cardinal-health-injunctive-relief-terms-20220225.pdf
44. Attorney General James Reaches $1.1 Billion Agreement with Big Three Distributors to Treat and Prevent Opioid Use in NYS, accessed September 23, 2025, https://ag.ny.gov/press-release/2021/attorney-general-james-reaches-11-billion-agreement-big-three-distributors-treat
45. Cardinal Health COVID-19 response plan, accessed September 23, 2025, https://www.cardinalhealth.com/content/dam/corp/web/documents/infographic/cardinal-health-covid-19-infographic.pdf
46. Building supply chain resiliency – Cardinal Health Newsroom, accessed September 23, 2025, https://newsroom.cardinalhealth.com/2021-12-03-Building-supply-chain-resiliency
47. Investor Day 2025: Momentum, strong performance and multi-year growth, accessed September 23, 2025, https://newsroom.cardinalhealth.com/2025-06-25-Investor-Day-2025-Momentum,-strong-performance-and-multi-year-growth
48. Cardinal Health Reports Second Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook – Jan 30, 2025, accessed September 23, 2025, https://newsroom.cardinalhealth.com/2025-01-30-Cardinal-Health-Reports-Second-Quarter-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2025-Outlook
49. CAH 2025 Investor Day Presentation, accessed September 23, 2025, https://s201.q4cdn.com/566741227/files/doc_presentation/2025/CAH-2025-Investor-Day-Presentation.pdf
50. Resources – Investor FAQs – Cardinal Health, Inc., accessed September 23, 2025, https://ir.cardinalhealth.com/resources/investor-faqs/default.aspx
51. The 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors – Drug Channels Institute, accessed September 23, 2025, https://drugchannelsinstitute.com/products/industry_report/wholesale/
52. CAH – Cardinal Health PE ratio, current and historical analysis, accessed September 23, 2025, https://fullratio.com/stocks/nyse-cah/pe-ratio
53. Cardinal Health PE Ratio 2010-2025 | CAH – Macrotrends, accessed September 23, 2025, https://www.macrotrends.net/stocks/charts/CAH/cardinal-health/pe-ratio
54. Cardinal Health, Inc. – Enterprise Value – Wisesheets, accessed September 23, 2025, https://www.wisesheets.io/enterprise-value/CAH
55. MCK – Mckesson PE ratio, current and historical analysis – FullRatio, accessed September 23, 2025, https://fullratio.com/stocks/nyse-mck/pe-ratio
56. COR – Cencora PE ratio, current and historical analysis – FullRatio, accessed September 23, 2025, https://fullratio.com/stocks/nyse-cor/pe-ratio
57. Jason Hollar – Cardinal Health, accessed September 23, 2025, https://www.cardinalhealth.com/en/about-us/our-people/our-leaders/jason-hollar.html
58. Steve Mason – Cardinal Health, accessed September 23, 2025, https://www.cardinalhealth.com/en/about-us/our-people/our-leaders/steve-mason.html
59. Our Leaders | Cardinal Health, accessed September 23, 2025, https://www.cardinalhealth.com/en/about-us/our-people/our-leaders.html